Terms: = Prostate cancer AND SOX2, MGC2413, 6657, ENSG00000181449, MCOPS3, P48431, ANOP3 AND Treatment
61 results:
1. treatment-related Neuroendocrine prostate Carcinoma-Diagnostic and Molecular Correlates.
Gopalan A
Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
[TBL] [Abstract] [Full Text] [Related]
2. prostate cancer Stem Cells: Biology and treatment Implications.
Koukourakis IM; Platoni K; Kouloulias V; Arelaki S; Zygogianni A
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834336
[TBL] [Abstract] [Full Text] [Related]
3. Knocking down sox2 overcomes the resistance of prostate cancer to castration via notch signaling.
Du Z; Chen X; Zhu P; Lv Q; Yong J; Gu J
Mol Biol Rep; 2023 Nov; 50(11):9007-9017. PubMed ID: 37716921
[TBL] [Abstract] [Full Text] [Related]
4. Transposable Elements Are Co-opted as Oncogenic Regulatory Elements by Lineage-Specific Transcription Factors in prostate cancer.
Grillo G; Keshavarzian T; Linder S; Arlidge C; Mout L; Nand A; Teng M; Qamra A; Zhou S; Kron KJ; Murison A; Hawley JR; Fraser M; van der Kwast TH; Raj GV; He HH; Zwart W; Lupien M
Cancer Discov; 2023 Nov; 13(11):2470-2487. PubMed ID: 37694973
[TBL] [Abstract] [Full Text] [Related]
5. Overexpression of sox2 Gene by Histone Modifications: sox2 Enhances Human prostate and Breast cancer Progression by Prevention of Apoptosis and Enhancing Cell Proliferation.
Kar S; Niharika ; Roy A; Patra SK
Oncology; 2023; 101(9):591-608. PubMed ID: 37549026
[TBL] [Abstract] [Full Text] [Related]
6. Exportin 1 inhibition prevents neuroendocrine transformation through sox2 down-regulation in lung and prostate cancers.
Quintanal-Villalonga A; Durani V; Sabet A; Redin E; Kawasaki K; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Shah NS; Chow A; Bhanot UK; Linkov I; Asher M; Yu HA; Qiu J; de Stanchina E; Patel RA; Morrissey C; Haffner MC; Koche RP; Sawyers CL; Rudin CM
Sci Transl Med; 2023 Aug; 15(707):eadf7006. PubMed ID: 37531417
[TBL] [Abstract] [Full Text] [Related]
7. Pretreatment of prostate cancer cells with salinomycin and Wnt inhibitor increases the efficacy of cabazitaxel by inducing apoptosis and decreasing cancer stem cells.
Serttas R; Erdogan S
Med Oncol; 2023 Jun; 40(7):194. PubMed ID: 37264204
[TBL] [Abstract] [Full Text] [Related]
8. CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners.
Söhngen C; Thomas DJ; Skowron MA; Bremmer F; Eckstein M; Stefanski A; Driessen MD; Wakileh GA; Stühler K; Altevogt P; Theodorescu D; Klapdor R; Schambach A; Nettersheim D
FEBS J; 2023 Oct; 290(20):4864-4876. PubMed ID: 37254618
[TBL] [Abstract] [Full Text] [Related]
9. sox2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axis.
Williams A; Gutgesell L; de Wet L; Selman P; Dey A; Avineni M; Kapoor I; Mendez M; Brown R; Lamperis S; Blajszczak C; Bueter E; Kregel S; Vander Griend DJ; Szmulewitz RZ
Cancer Lett; 2023 Jul; 565():216209. PubMed ID: 37169162
[TBL] [Abstract] [Full Text] [Related]
10. Total flavonoids of Litchi seed attenuate stem cell-like properties in breast cancer by regulating Notch3 signaling pathway.
Liao Y; Luo Z; Liu Y; Xue W; He S; Chen X; Ren H; Yang X; Zhu D; Su Z; Huang Q; Guo H
J Ethnopharmacol; 2023 Apr; 305():116133. PubMed ID: 36603788
[TBL] [Abstract] [Full Text] [Related]
11. TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer.
Fan L; Gong Y; He Y; Gao WQ; Dong X; Dong B; Zhu HH; Xue W
Oncogene; 2023 Feb; 42(8):559-571. PubMed ID: 36544044
[TBL] [Abstract] [Full Text] [Related]
12. Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs.
Li K; Sun X; Zha R; Liu S; Feng Y; Sano T; Aryal UK; Sudo A; Li BY; Yokota H
Theranostics; 2022; 12(7):3084-3103. PubMed ID: 35547745
[No Abstract] [Full Text] [Related]
13. Role of Resveratrol as Radiosensitizer by Targeting cancer Stem Cells in Radioresistant prostate cancer Cells (PC-3).
El-Benhawy SA; Morsi MI; Fahmy EI; Soula MA; Khalil FAZF; Arab AR
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3823-3837. PubMed ID: 34967561
[TBL] [Abstract] [Full Text] [Related]
14. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract] [Full Text] [Related]
15. THOC2 and THOC5 Regulate Stemness and Radioresistance in Triple-Negative Breast cancer.
Bai X; Ni J; Beretov J; Wang S; Dong X; Graham P; Li Y
Adv Sci (Weinh); 2021 Dec; 8(24):e2102658. PubMed ID: 34708581
[TBL] [Abstract] [Full Text] [Related]
16. Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer.
Lin J; Chen Z; Li Z; Nong D; Li X; Huang G; Hao N; Liang J; Li W
Oncol Rep; 2021 Sep; 46(3):. PubMed ID: 34296309
[TBL] [Abstract] [Full Text] [Related]
17. Long non-coding RNA LINC00649 regulates YES-associated protein 1 (YAP1)/Hippo pathway to accelerate gastric cancer (GC) progression via sequestering miR-16-5p.
Wang H; Di X; Bi Y; Sun S; Wang T
Bioengineered; 2021 Dec; 12(1):1791-1802. PubMed ID: 33975517
[TBL] [Abstract] [Full Text] [Related]
18. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.
Okasho K; Mizuno K; Fukui T; Lin YY; Kamiyama Y; Sunada T; Li X; Kimura H; Sumiyoshi T; Goto T; Kobayashi T; Lin D; Wang Y; Collins CC; Inoue T; Ogawa O; Akamatsu S
Cancer Sci; 2021 Jul; 112(7):2781-2791. PubMed ID: 33960594
[TBL] [Abstract] [Full Text] [Related]
19. The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.
Labrecque MP; Alumkal JJ; Coleman IM; Nelson PS; Morrissey C
Endocr Relat Cancer; 2021 Jul; 28(8):T51-T66. PubMed ID: 33792558
[TBL] [Abstract] [Full Text] [Related]
20. Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells.
Pérez G; López-Moncada F; Indo S; Torres MJ; Castellón EA; Contreras HR
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760173
[TBL] [Abstract] [Full Text] [Related]
[Next]
